Modius Sleep device from Ireland-based Neurovalens treating chronic insomnia now available for purchase

image source: PR Newswire press release

Neurovalens, a global health-tech leader in neurotechnology, announced the launch of its first product, Modius Sleep, to treat chronic insomnia. Neurovalens received medical device clearance from the U.S. Food & Drug Administration for two of its products: Modius Sleep (in October of 2023), which is available now in the U.S. through a physician prescription, and Modius Stress (in March of 2024), which is not yet available for purchase.

The company's Modius technology is non-invasive and taps into the body's natural processes. It enhances health by using low-level electrical signals that stimulate the vestibular nerve in the brain to regulate key functions like sleep and anxiety. Modius Sleep is Neurovalens' first FDA-cleared physician-prescribed medical device. It is a non-invasive and drug-free solution to help improve sleep for patients with chronic insomnia. Featured in the prestigious medical journal Brain Stimulation, a recent clinical trial showed that after four weeks, Modius Sleep improved sleep for 95 percent of trial participants.

Modius Sleep is a headset used in the comfort of a patient's home for 30 minutes each evening. The device uses electrical vestibular nerve stimulation (VeNS) which is a non-invasive therapeutic method shown to improve chronic insomnia. The device sends a safe electrical pulse into the vestibular nerve, influencing the areas of the hypothalamus and brainstem that control circadian rhythm and sleep patterns. Patients must qualify to purchase.